Korean aesthetic device company reported on Wednesday the receipt of the US Food and Drug Administration's 510 (K) clearance to market WONTECH SANDRO DUAL laser device across the global markets, including the US and Europe.
Recently, the SANDRO DUAL was launched in Korea Nd:YAG & Alexandrite based lasers mounted on one device.
According to the company, the SANDRO DUAL can be implemented in the hybrid mode in a short time difference between two wavelengths of 755nm and 1064nm. The energy is accurately delivered to a specific area to deliver an effective and quick treatment in hair removal as well as whitening without damaging surrounding tissue.
In addition, the the SANDRO DUAL's SCS (Skin Cooling Spray) cooling system minimizes patient discomfort from pain, swelling and redness.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval